TNG Transgene SA

0.7590USD0.6920 EUR · EPA-0.72%Mkt Cap: 211.19M USDP/E: —

Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase II cl…

Key Statistics

Company
Market Cap211.19M USD
Enterprise Value108.81M USD
Revenue (TTM)6.17M USD
Gross Profit-28.28M USD
Net Income (TTM)-41.16M USD
Revenue/Share0.03 USD
Last Price0.7590 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees152
CountryFR
SectorHealthcare
IndustryBiotechnology
ISINFR0005175080
Valuation
P/E (Trailing)—
P/E (Forward)-3.15
PEG3.08
EV/EBITDA-2.97
EV/Revenue17.64
P/S34.24
P/B1.74
EPS (TTM)-0.19 USD
EPS (Forward)-0.24 USD
52W Range
0.73493% of range1.497
52W High1.497 USD
52W Low0.7349 USD
Profitability
Gross Margin0.00%
Oper. Margin-617.69%
EBITDA Margin0.00%
Profit Margin-7657.96%
ROE-30.82%
ROA-27.03%
ROIC-344.18%
ROCE-26.86%
Growth
Revenue Growth-34.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF-40.63M USD
CapEx (TTM)923.51K USD
FCF Margin-433.30%
FCF Yield-12.66%
Net Debt-99.44M USD
Net Debt/EBITDA2.71
Net Debt/FCF—
Balance Sheet
Debt/Equity0.00
Current Ratio9.40
Quick Ratio8.95
Book Value/Sh0.44 USD
Cash/Share0.37 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)1.206 USD
Upside (mean)+59.0%
Target Range1.206 USD – 1.206 USD
# Analysts1
Ownership
Shares Out.278.26M
Float48.96M
Insiders80.78%
Institutions0.00%
Technical
SMA 500.8188 (-7.3%)
SMA 2000.8449 (-10.2%)
Beta0.79
S&P 52W Chg12.00%
Avg Vol (30d)77.90K
Avg Vol (10d)75.59K
Technical Indicators
RSI (14)38.8
MACD-0.0062
MACD Signal-0.0026
MACD Hist.-0.0036
BB Upper0.8560 USD
BB Middle0.7945 USD
BB Lower0.7329 USD
BB Width15.49%
ATR (14)0.0247 USD
Vol Ratio (20d)0.29x

About Transgene (EPA: TNG)

›

Transgene (EPA: TNG) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 152 employees.

The shares were at 0.6920 EUR on 19 November 2026, down 45.1% over 52 weeks. Its 52-week range is 0.6700 EUR to 1.365 EUR: the price is 49.3% below the high and 3.3% above the low.

Its market capitalisation is 192.55M EUR.

Transgene reports return on equity of -30.8% and revenue down 34.6% year over year.

It holds more cash than debt, a net cash position of 90.66M EUR. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. One analyst covers the stock, with an average rating of Strong Buy; their mean price target of 1.100 EUR is 59.0% above the current price.